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SUMMARY
Specific active immunization with dengue type 2 virus (DV)-induced cytokine, cytotoxic factor
(CF), prevents CF-mediated pathology in mice. The present study was undertaken to determine
the optimum dose of CF and the effect of different adjuvants on the immune response as assessed
by the study of anti-CF antibody titre by ELISA and protection against increase in capillary
permeability to challenging dose of 3 Ag CF. The maximum protection of 94 4% against increase
in capillary permeability was observed at week 4 after immunization with 5 Ag dose of CF mixed
with Freund's incomplete adjuvant (FIA), which gradually decreased to 21 ± 10% on week 24.
With a dose of 10 ig the protection obtained was 79 ± 5%, but persisted for a longer time at a
higher level. The response was poor with 1 tg dose of CF. The mean anti-CF antibody titres
gradually decreased after reaching the peak at week 4 after immunization. Mice immunized with
different adjuvants emulsified with 5 pg CF were challenged at different intervals with 3 Aig CF.
Maximum protection observed with CF + tetanus toxoid (TT) and 84/246 was about 93 ± 2% and
97 ± 2%, while that with alhydrogel was 33 12% and with bacille Calmette-Guerin (BCG) was
67 ± 4%. At week 24 after immunization, however, the best response was obtained with 10 ,ug of
adjuvant 84/246. Intracerebral challenge with 10 or 100 LD50 dose of dengue type 2 virus showed
significantly prolonged mean survival time and delayed onset of signs of sickness in immunized
mice compared with normal mice. The maximum survival time was with adjuvant 84/246 even at
week 24. The findings thus show that the optimum dose of CF is 5 ptg and the adjuvant of choice is
84/246.
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INTRODUCTION
A cytokine called cytotoxic factor (CF) is produced during
dengue virus infection of mice by T cells of the spleen, which is
responsible for producing various pathological lesions that are
seen in human dengue infection [1-8]. Thus CF appears to be a
pathogenesis-related protein. Recently we have demonstrated
the presence of a CF-like protein in the sera of human cases of
dengue fever (DF), dengue haemorrhagic fever and shock
syndrome (DHF/DSS) by ELISA and dot blot tests. Further,
a CF-like protein has been purified from the sera ofDHF cases
by ion exchange and affinity chromatography (U. C.
Chaturvedi et al., unpublished data). Human peripheral
blood CD4+ T cells have been shown to produce CF on in
vitro stimulation with dengue type 2 virus [9]. This has greatly
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enhanced the significance of CF in dengue pathogenesis. An
effective vaccine for dengue virus infection is not yet available,
so we have investigated the concept of 'anti-disease vaccine' by
immunizing mice with CF mixed with Freund's incomplete
adjuvant (FIA) and challenging them with CF. Almost
complete protection against CF challenge was observed at
week 4 of immunization which was dependent on the
challenging dose of CF. This showed successful prevention of
a cytokine-mediated pathology by specific active vaccination
[10]. This initial success in 'anti-disease vaccination' has raised
several questions. For example, what is the minimum dose of
CF required for better results? Which adjuvant is best for
immunization? The present study was planned to answer
some of these questions.
MATERIALS AND METHODS
Mice
The study was carried out on inbred Swiss albino mice aged 2-3
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months, obtained from the colony maintained in this
Department.
Virus
Dengue type 2 virus (DV), strain P23085, obtained from the
National Institute of Virology (Pune, India) was used in the
form of infected mouse brain suspension [11]. The virus titre
was calculated by the method of Reed & Muench [12] and
expressed as log 10 LD50 for 301LI of the brain suspension.
Normal brain homogenate (NMB) was used as control.
Preparation of the cytotoxic factor
CF was prepared from the spleen cells of DV-infected mori-
bund mice. CF was purified from culture supernatant with
Pharmacia low pressure liquid chromatography system using
Sephacryl S-200 gel column [13,14], and dried in Speed Vac
(Savant Instrument Inc., Farmingdale, NY). The amount of
protein was estimated by the method of Lowry et al. [15]. The
purity of CF was established by SDS-PAGE. Normal spleen
cell culture supernatant (NF) was similarly prepared and used
as a control.
Immunization ofmice
Mice were immunized with different doses of purified CF
emulsified in various adjuvants and injected subcutaneously
on the dorsal aspect. The adjuvants used were FIA (Sigma
Chemical Co., St Louis, MO), tetanus toxoid (TT; Behring
Pharma Pvt. Ltd., Sathamrai A.P., India), alhydrogel (CDH
Laboratory Reagents, New Delhi, India), bacille Calmette-
Guerin (BCG; BCG Vaccine Laboatory, Madras, India), and
a glycopeptide structurally related to muramyl dipeptide
(MDP), N-acetyl normuramyl-L-N-methylalanyl-D-isogluta-
mine octalymide (Compound no. 84/246) was synthesized at
the Central Drug Research Institute (Lucknow, India) [16].
Control mice were similarly treated with adjuvant alone or
mixed with NF. At different intervals blood was collected from
the eyes of mice, sera were separated and stored at -20'C.
Assay of capillary permeability
Measurement of leakage of plasma protein-bound Evans blue
dye from the vascular compartment into the peritoneal cavity
of the mouse was used to estimate the integrity of capillary
permeability as described previously [5]. Briefly, mice were
inoculated intravenously with 100,1l of Evans blue dye solution,
followed 5 min later with CF intraperitoneally. After 30 min
mice were anaesthetized and the peritoneal cavity was washed
with 5 ml saline. The lavage fluid was collected and filtered
through glass wool column and made up to final volume 10 ml.
Optical density at 590 nm was determined with a spectro-
photometer. The protein contents of the fluid were calculated
as jg protein/ml. The results were expressed as permeability
index (PI). Control mice were inoculated with NF. The per cent
protection in immunized mice was calculated as follows:
PI =
100 x (protein in CF inoculated mice - background value)
(protein in NF inoculated mice - background value) - 100
Per cent protection =
(PI in immunized mice - PI in control mice)
X 100
PI in control mice
ELISA
The technique of Voller et al. [17] was used with some
modifications to set up ELISA [10]. Briefly, 3 ng of purified
CF in 100 pI PBS were added to the flat-bottomed ELISA plate
(Titertek Immuno Assay plates 77-173-05; Flow Labs,
Zwanenburg, The Netherlands), incubated overnight at 37°C
in humidified atmosphere. The plate was washed three times
with PBS containing 0-05% Tween 20 (PBS-T) and blocked
with blocking buffer containing 1% milk protein (Lactogen-1
Milk Powder; Nestle India Ltd., New Delhi, India) in PBS for
1 h. The plate was washed again three times with PBS-T, and
100 Mil of 1: 200 diluted serum from immunized or normal mice
sera for control were added and the plate was incubated at 37°C
for 1 h. After washing the plate, 100 p1 of protein A conjugated
with horseradish peroxidase (HRP; a gift from the National
Institute of Immunology, New Delhi, India) (1:10000) were
added and incubated at 37°C for 1 h. The plate was washed and
a 100,ul mixture of o-phenylenediamine and H202 in citrate
buffer (0-02 M) pH 5*0 was added, and absorbance was read at
492 nm. Each serum sample was tested in duplicate and the
mean absorbance in wells without CF was subtracted from the
mean absorbance in wells with CF before analysis. The cut off
value for seropositivity was determined by adding 2 x s.d. to
mean absorbance of normal mouse serum control.
RESULTS
Immunization with different doses ofCF
Mice were immunized with different doses of CF emulsified in
FIA. The immunized and the control mice were challenged with
3 ,ug of purified CF and capillary permeability was assayed to
find the protective effect at different periods after immuniza-
tion. Indication of the protective response was per cent decrease
in CF-induced increase in capillary permeability in immunized
mice compared with normal control mice. The data sum-
marized in Fig. 1 show that protection against challenge with
CF was maximum (94 ± 4%) at week 4 with an immunizing
dose of 5 Mg CF which gradually decreased to 21 + 10% on
week 24. With the immunizing doses of 1 or 10,g of CF the
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Fig. 1. Effect of immunizing dose of cytoxic factor (CF) on the capacity
to protect mice against increase in capillary permeability by challenge
with 3 pg of CF at different periods. Mice were immunized with 1 jig
(0), 5 jg (0), or 1O jig (O) CF emulsified in Freund's incomplete
adjuvant (FIA). Control mice were treated with normal spleen cell
culture supernatant (NF) mixed with FIA, while those for background
values were treated with FIA alone. Each point represents mean ± s.d.
from 8- 10 mice.
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Fig. 2. Anti-cytotoxic factor (CF) antibody titre in mice immunized
with different doses of CF. Sera collected from individual mice of Fig. I
were tested by ELISA. Mice immunized with I plg (0), Splg (0), or
pg (0) CF. Mean OD + 2 s.d. on sera from control mice is shown as
dotted horizontal line.
protection obtained was less than 79 ± 5%o. Mice immunized
with different doses of CF were bled at different periods and the
sera from individual mice were assayed for the presence of anti-
CF antibodies by ELISA. The findings summarized in Fig. 2
show that with an immunizing dose of I jig, mean antibody titre
gradually decreased after reaching a peak at week 4 of immu-
nizationi. With 10 lig of immunization dose seropositivity was
1000/0, and higher antibody titres persisted up to week 24 of
observation. The mean antibody titre gradually decreased after
week 12 with 1 and 5 pIg immunization dose.
Effect of a(djiuvaui(. 0on i fnlu/iogeniiiitci of ('F
Groups of mice were immunized with 5 lg CF mixed with
different adjuvants to study the efficacy of the adjuvant.
Control mice were given only the adjuvant. Protection against
aIn increase in capillary permeability to challenge with 3 pig of
CF was studied as described earlier. The results observed after
week 4 of immunization showed maximum protection of
97 ± 2% in mice immunized with CF + 84, 246. Mice
immunized with CF + TT showed 93 6% and with
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Fig. 3. Protective effect of immunization of mice with 5 pig of cytotoxic
factor (CF) mixed with different adjuvants against increased capillary
permeability to a challenge with 3 lpg of CF-. Control mice were given
normal spleen cell culture supernatant (NF) mixed with different
adjuvants and those treated with the adjux ant alone yielded back-
ground values. Each point represents mean s.d. from 10 mice.
Freund's incomplete adjuvant (FIA) (0), 84 246 (0), tetanus toxoid
(TT) (0), bacille Callmette Guerin (BCG) (U), and alhydrogel (A).
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Fig. 4. Dose response to challenge with various doses ofcytotoxic factor
(CF). Mice immunized with 5 plg of CF mixed with tetanus toxoid (TT)
(0). Freund's incomplete adjuvant (FIA) (L) or 84 246 (U) were
challenged with various doses of CF and protection against increase
in capillary permeability was recorded. The controls were as described
above. Fach point represents mean ± s.d. from 10 12 mice.
CF + FIA 94 ± 4% protection, while that with alhydrogel
was 33 ± 12% and with BCG 67 ± 4%. At week 24 of
immunization. however, the best response (72 ± 60%) was
obtained with adjuvant 84 246 (Fig. 3).
In another set of experiments the dose response of CF
challenge was investigated in mice immunized by CF mixed
with TT or FIA or 84 246. For this, mice were taken at week 4
after immunization. Groups of immunized and control mice
were challenged with various doses of CF and per cent protec-
tion was calculated. The data presented in Fig. 4 show that the
capacity of immunized mice to resist the CF-induced increase in
capillary permeability declined in a dose-dependent manner
with all the three adjuvants, but the decline was least with 84
246.
An attempt was made to find the optimum dose of 84i246
adjuvant. Mice were immunized with 5 pig of CF mixed with
different doses of adjuvant 84/246 and challenged with 3 pig of
purified CF at week 4 after immunization, and capillary
permeability was assayed. The data SUimmarized in Fig. 5
show that IO ig dose of the adjuvant is best, as up to week 24
the protection level was 72 ± 6%. With higher doses of the
adjuvant the background values were very high (data not
shown).
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Fig. 5. Eflect of various immunizing doses of 84 246 mixed with 5 pig of
cytotoxic factor (CF) on the capacity to protect against increase ill
capillary permeability to challenge with 3 pg Cl at week 4. Each group
consisted of 10 mice.
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Effect of challenge of immunized mice with DV
Mice immunized with different adjuvants mixed with 5 pg of
CF and normal control mice were inoculated intracerebrally
with 10 or 100 LD50 of DV, and the sickness and mortality ratio
were recorded over a period of 21 days. The normal mice
inoculated with DV (100 LD50) remained healthy up to day 5
post-infection (p.i.), and on day 6 arching of the back and
ruffling of the fur occurred. A severe sickness and paralysis of
the limbs occurred on days 8-9, and all mice died by day 12 p.i.
The events shifted to the right by 1 day in mice given 10 LD50 of
DV. The mean survival times were 10-2 ± 0-4 and 11 4 + 0 5
days with 100 and 10 LD50 of DV, respectively (Fig. 6a). At
week 4 after immunization the mean survival time was 15-16
days (P =< 0 001) with 10 LD50 and 12-16 4 days (P > 0-05
to < 0-001) with 100 LD50 of the virus in different groups of
mice. At 24 weeks after immunization the mean survival time
was prolonged only in mice given 84/246 adjuvant, being
19 ± 1 5 days with 10 LD50 and 16± 0-8 days with 100 LD50
of DV (Fig. 6a,b). The immunized mice did not develop the
milder signs of illness; they developed paralysis and died within
24 h.
DISCUSSION
The main finding of this series of experiments is that 84/246 is
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Fig. 6. Cumulative mortality ratio of mice injected with dengue type 2
virus (DV) intracerebrally. Normal mice give 10 LD50 (0) or 100 LD50(0) of DV. Mice immunized with cytotoxic factor (CF) mixed with
Freund's incomplete adjuvant (FIA) (U), tetanus toxoid (TT) (A), or
84/246 (A) were challenged with 10 LD50 of DV, while second set of
mice immunized with CF mixed with FIA (U), TT (V) or 84/246 (V)
were challenged with 100 LD50 of DV intracerebrally. (a) At 4 weeks
after immunization. (b) At 24 weeks after immunization. Each group
consisted of six mice.
the best adjuvant for immunization of mice. A complete
protection (97 + 2%) against increase in capillary permeability
to a challenging dose of 3 jig/mouse was observed at week 4
after immunization. The peak protection obtained with 10 ig
immunizing dose was 79 ± 5%, but persisted at a higher level
for a longer period. The route of exposure, in vivo persistence,
dose, frequency and physical properties of antigen have an
influence on the type and length of immunity. Native T cells
proliferate during their encounter with antigens, and an
expanded pool of memory T cells develops and persists even
for a life time [18]. For an optimum immune response, booster
doses of an antigen are required. Further, the adjuvants also
influence the immune response to an antigen. FIA and
Corynebacterium parvum enhance significantly DTH response,
and saponin enhances humoral immune response [19].
Aluminium-containing compounds such as hydroxides and
phosphates are approved for clinical use, but they are not
active with all immunogens and stimulate only humoral
responses [20]. The protection observed at week 4 was above
90% by using TT or 84/246 as adjuvant, whereas with BCG and
aihydrogel it was 67 ± 4% and 33 ± 12%, respectively. At week
24 protection continued to be higher (72 + 6%) only with
adjuvant 84/246. Challenge of immunized mice with DV
showed significantly prolonged mean survival time, absence
of signs of illness like arching of the back and ruffling of the fur,
and delayed onset of parafysis compared with normal mice.
Peak response was obtained with adjuvant 84/246, which
increased the mean survival time to 16-19 days in different
groups of mice. These findings support our earlier observations
[10]. Interferon-gamma (IFN--y) selectively augments the
production of IgG2a antibodies in mice [21]. The depot type
adjuvants (FIA, Freund's complete adjuvant (FCA) and
alhydrogel) and MDP are effective in promoting the immune
response to bovine serum albumin (BSA) [19]. The immuno-
stimulant activity of 84/246 is comparable to that ofMDP [16].
Immunoadjuvants are a class of compounds with a large
variety of conformations and act via different pathways.
Their biological properties depend upon their capacity to
activate selectively Thl or Th2 cells that control the major
features of specific immune response [22]. It has been shown
that FCA activate Thl cells and alhydrogel Th2 cells of mice,
but it may also be relevant to humans [23]. The basis of
adjuvanticity of microbial components could be their recogni-
tion by phylogenetically ancient receptors present on accessory
cells. This recognition induces them to produce cytokines which
selectively stimulate Thl or Th2 cells [24].
A question that needs to be addressed is whether such a
vaccine could ever find practical use, because it is based on
immunization against a self protein. Presence of autoantibodies
to a number of cytokines has been described and their role
discussed. Anti-cytokine autoantibodies are known to block
the activity of the cytokines, and are found in the serum for
IL-la, IL-2, IL-4, IL-6, IL-8, IL-10, tumour necrosis factor-
alpha (TNF-a) and IFN-a. Small complexes between such
antibodies and cytokines do not activate complement if IgG4
antibodies are involved, and do not precipitate in vivo, but are
active as inflammatory complexes [25]. Bendtzen et al. [26] have
proposed that a major role of anti-cyctokine autoantibodies is
to facilitate, rather than neutralize, functions ofcytokines in the
body by acting as specific physiological carriers and regulators
of cytokines. For effective immunization it is essential that such
© 1995 Blackwell Science Ltd, Clinical and Experimental Immunology, 102:496-500
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epitopes of cytokines are used which generate neutralizing
antibody only.
Ideally an adjuvant should induce both high antibody levels
and strong cell-mediated immunity and should be safe and
comfortable. FCA is unacceptable for human use, while FIA is
no longer used, although there is no evidence that it produces
any adverse effects. Alum remains an important adjuvant for
administration with preventive vaccines and has recently been
used with synthetic malaria vaccine. In some of the clinical
trials cytokines like interferons and IL-2 have been tried as
adjuvant. CF is an unique cytokine induced by DV which is
responsible for the production of most of the pathological
lesions which could be prevented by active immunization [10].
The effect of the vaccine could be enhanced by using booster
doses and appropriate adjuvants. The effect of booster doses
remains to be investigated.
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